{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:25:26Z","timestamp":1790673926854,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study was conducted to evaluate the potential genetic and non-genetic factors contributing to plasma trough concentration-to-dose (<jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>\/<jats:italic>D<\/jats:italic>) ratio of valproic acid (VPA) in pediatric patients with epilepsy.<\/jats:p><jats:p><jats:bold>Study Design:<\/jats:bold> A single-center, retrospective cohort study was performed by collecting data from 194 children aged 1\u201314 years between May 2018 and November 2018. The oral solution (<jats:italic>n<\/jats:italic> = 135) group and the sustained-release (SR) tablet group (<jats:italic>n<\/jats:italic> = 59) were defined, and the plasma VPA <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub> was measured. Twenty-six single-nucleotide polymorphisms (SNPs) were chosen for genotyping with the MassARRAY system. A multiple logistic regression model was used for data analysis.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Body weight (BW) and age were positively correlated with the <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>\/<jats:italic>D<\/jats:italic> ratio in 194 patients, but the positive correlation disappeared after the patients were divided into oral solution and SR tablet subgroups. The average <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>\/<jats:italic>D<\/jats:italic> ratio was significantly increased by 2.11-fold (<jats:italic>P<\/jats:italic> = 0.000) in children who took VPA SR tablets compared with children who were administered VPA oral solutions. No significant association between genetic variants and the <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>\/<jats:italic>D<\/jats:italic> ratio was found, even for the five well-studied SNPs, namely <jats:italic>UGT2B7<\/jats:italic> G211T, C802T, C161T, T125C, and <jats:italic>CYP2C9<\/jats:italic><jats:sup>*<\/jats:sup><jats:italic>3<\/jats:italic> A1075C. However, a significant association between the <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>\/<jats:italic>D<\/jats:italic> ratio and <jats:italic>UGT1A6\/9<\/jats:italic> Del&amp;gt;A (rs144486213) was observed in the VPA oral solution group, but not in the VPA SR tablet group.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> The dosage forms of sodium valproate, rather than BW, age, or genetic polymorphisms, significantly affected the VPA <jats:italic>C<\/jats:italic><jats:sub>0<\/jats:sub>\/<jats:italic>D<\/jats:italic> ratios in pediatric patients with epilepsy. Based on our findings, switching the dosage form between solution and SR tablet should be performed cautiously. Total daily dose adjustment should be considered, and the plasma concentration, seizure-control effect, and adverse drug reaction should also be monitored very closely.<\/jats:p>","DOI":"10.3389\/fped.2020.599044","type":"journal-article","created":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T07:09:46Z","timestamp":1611126586000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Genetic and Non-genetic Factors Contributing to the Significant Variation in the Plasma Trough Concentration-to-Dose Ratio of Valproic Acid in Children With Epilepsy"],"prefix":"10.3389","volume":"8","author":[{"given":"Ze-Yue","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Li","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Jing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ze-Jun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Chun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Peng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan-Sheng","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,1,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1093\/brain\/awz195","article-title":"Incidence and phenotypes of childhood-onset genetic epilepsies: a prospective population-based national cohort","volume":"142","author":"Symonds","year":"2019","journal-title":"Brain."},{"key":"B2","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1684\/epd.2015.0736","article-title":"Incidence, prevalence and aetiology of seizures and epilepsy in children","volume":"17","author":"Camfield","year":"2015","journal-title":"Epileptic Disord."},{"key":"B3","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1212\/CON.0000000000000712","article-title":"Antiepileptic drug treatment of epilepsy in children","volume":"25","author":"Moosa","year":"2019","journal-title":"Continuum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/s1474-4422(15)00314-2","article-title":"Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug","volume":"15","author":"Tomson","year":"2016","journal-title":"Lancet Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1528-1167.2008.01561.x","article-title":"Antiepileptic drugs\u2013best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE commission on therapeutic strategies","volume":"49","author":"Patsalos","year":"2008","journal-title":"Epilepsia."},{"key":"B6","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1097\/FTD.0000000000000546","article-title":"Therapeutic drug monitoring of antiepileptic drugs in epilepsy: a 2018 update","volume":"40","author":"Patsalos","year":"2018","journal-title":"Ther Drug Monit."},{"key":"B7","doi-asserted-by":"publisher","first-page":"4107","DOI":"10.12659\/msm.897626","article-title":"Association of UGT2B7 and UGT1A4 polymorphisms with serum concentration of antiepileptic drugs in children","volume":"22","author":"Du","year":"2016","journal-title":"Med Sci Monit."},{"key":"B8","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00228-016-2087-0","article-title":"Impact of age, gender and CYP2C9\/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid-a large-scale study based on naturalistic therapeutic drug monitoring data","volume":"72","author":"Smith","year":"2016","journal-title":"Eur J Clin Pharmacol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2174\/1381612825666190329145428","article-title":"Valproic acid and the liver injury in patients with epilepsy: an update","volume":"25","author":"Guo","year":"2019","journal-title":"Curr Pharm Des."},{"key":"B10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s00228-017-2395-z","article-title":"Effect of UGT2B7 genotypes on plasma concentration of valproic acid: a meta-analysis","volume":"74","author":"Wang","year":"2018","journal-title":"Eur J Clin Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/FTD.0000000000000271","article-title":"Effects of UGT2B7 genetic polymorphisms on serum concentrations of valproic acid in chinese children with epilepsy comedicated with lamotrigine","volume":"38","author":"Wang","year":"2016","journal-title":"Ther Drug Monit."},{"key":"B12","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.eplepsyres.2015.04.015","article-title":"The influence of UGT2B7 genotype on valproic acid pharmacokinetics in Chinese epilepsy patients","volume":"114","author":"Sun","year":"2015","journal-title":"Epilepsy Res."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00228-015-1925-9","article-title":"Influence of valproic acid concentration and polymorphism of UGT1A4*3, UGT2B7\u2212161C > T and UGT2B7*2 on serum concentration of lamotrigine in Chinese epileptic children","volume":"71","author":"Liu","year":"2015","journal-title":"Eur J Clin Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"144","DOI":"10.5414\/CP203357","article-title":"A meta-analysis of the influence of UGT1A6 genetic polymorphisms on valproic acid pharmacokinetics","volume":"57","author":"Kim","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1111\/epi.13011","article-title":"Clinical significance of CYP2C9-status guided valproic acid therapy in children","volume":"56","author":"Budi","year":"2015","journal-title":"Epilepsia."},{"key":"B16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2217\/pme.14.82","article-title":"Phenoconversion of CYP2C9 in epilepsy limits the predictive value of CYP2C9 genotype in optimizing valproate therapy","volume":"12","author":"T\u00f3th","year":"2015","journal-title":"Per Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1007\/s00228-009-0712-x","article-title":"Effects of CYP2C19 and CYP2C9 genotypes on pharmacokinetic variability of valproic acid in Chinese epileptic patients: nonlinear mixed-effect modeling","volume":"65","author":"Jiang","year":"2009","journal-title":"Eur J Clin Pharmacol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.clineuro.2010.01.002","article-title":"The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients","volume":"112","author":"Tan","year":"2010","journal-title":"Clin Neurol Neurosurg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.eplepsyres.2017.02.015","article-title":"Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy","volume":"132","author":"Wang","year":"2017","journal-title":"Epilepsy Res."},{"key":"B20","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/epi.12043","article-title":"Extended-release antiepileptic drugs: a comparison of pharmacokinetic parameters relative to original immediate-release formulations","volume":"54","author":"Leppik","year":"2013","journal-title":"Epilepsia."},{"key":"B21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1212\/01.wnl.0000319958.37502.8e","article-title":"Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures","volume":"71","author":"Berg","year":"2008","journal-title":"Neurology."},{"key":"B22","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1111\/j.1528-1167.2007.01007.x","article-title":"Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes","volume":"48","author":"Andermann","year":"2007","journal-title":"Epilepsia."},{"key":"B23","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/S1474-4422(16)00014-4","article-title":"Generic-to-generic lamotrigine switches in people with epilepsy: the randomised controlled EQUIGEN trial","volume":"15","author":"Privitera","year":"2016","journal-title":"Lancet Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"l6096","DOI":"10.1136\/bmj.l6096","article-title":"Practical aspects of childhood epilepsy","volume":"367","author":"Petropoulos","year":"2019","journal-title":"BMJ"},{"key":"B25","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/s0387-7604(12)80148-3","article-title":"A comparative clinical and pharmacokinetic study of a new slow-release versus conventional preparations of valproic acid in children with intractable epilepsy","volume":"14","author":"Imaizumi","year":"1992","journal-title":"Brain Dev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/j.0013-9580.2005.39804.x","article-title":"Extended-release divalproex in child and adolescent outpatients with epilepsy","volume":"46","author":"Kernitsky","year":"2005","journal-title":"Epilepsia."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1111\/j.1600-0404.2011.01568.x","article-title":"Effects of the abrupt switch from solution to modified-release granule formulation of valproate","volume":"125","author":"Verrotti","year":"2012","journal-title":"Acta Neurol Scand."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.2217\/pgs.12.78","article-title":"Functional impact and prevalence of polymorphisms involved in the hepatic glucuronidation of valproic acid","volume":"13","author":"Chatzistefanidis","year":"2012","journal-title":"Pharmacogenomics."},{"key":"B29","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2217\/pgs-2016-0014","article-title":"UGT1A6- and UGT2B7-related valproic acid pharmacogenomics according to age groups and total drug concentration levels","volume":"17","author":"Chatzistefanidis","year":"2016","journal-title":"Pharmacogenomics."},{"key":"B30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/pgs.11.64","article-title":"Association of genetic variants in six candidate genes with valproic acid therapy optimization","volume":"12","author":"Hung","year":"2011","journal-title":"Pharmacogenomics."},{"key":"B31","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.seizure.2018.04.006","article-title":"Effects of UGT2B7, SCN1A and CYP3A4 on the therapeutic response of sodium valproate treatment in children with generalized seizures","volume":"58","author":"Feng","year":"2018","journal-title":"Seizure."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.2217\/pgs-2016-0030","article-title":"Influence of acylpeptide hydrolase polymorphisms on valproic acid level in Chinese epilepsy patients","volume":"17","author":"Wen","year":"2016","journal-title":"Pharmacogenomics."},{"key":"B33","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2133\/dmpk.DMPK-11-NT-144","article-title":"Effects of UGT1A6, UGT2B7, and CYP2C9 genotypes on plasma concentrations of valproic acid in chinese children with epilepsy","volume":"27","author":"Guo","year":"2012","journal-title":"Drug Metab Pharmacokinet."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jpm8010001","article-title":"Pharmacogenomics of CYP2C9: functional and clinical considerations","volume":"8","author":"Daly","year":"2017","journal-title":"J Pers Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1111\/jcpt.12835","article-title":"CYP2C9, CYP2C19, CYP2D6 and CYP3A5 polymorphisms in south-east and east asian populations: a systematic review","volume":"44","author":"Dorji","year":"2019","journal-title":"J Clin Pharm Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"S42","DOI":"10.1002\/jcph.1493","article-title":"Characterization of the ontogeny of hepatic UDP-glucuronosyltransferase enzymes based on glucuronidation activity measured in human liver microsomes","volume":"59","author":"Badee","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"key":"B38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1002\/cpt.1109","article-title":"Age- and genotype-dependent variability in the protein abundance and activity of six major uridine diphosphate-glucuronosyltransferases in human liver","volume":"105","author":"Bhatt","year":"2019","journal-title":"Clin Pharmacol Ther."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.599044\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T07:09:48Z","timestamp":1611126588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2020.599044\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,20]]},"references-count":38,"alternative-id":["10.3389\/fped.2020.599044"],"URL":"https:\/\/doi.org\/10.3389\/fped.2020.599044","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,20]]},"article-number":"599044"}}